Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
-
Legal situation KBO
Vrijwillige ontbinding – vereffening according to the CBE.
Financials
Financial year 2024
THERATOPIX PHARMA from Liège, company number BE0738446251, closed financial year 2024 with a result of € -205,565 after tax. For that financial year THERATOPIX PHARMA recorded revenue of € 74,768 and equity of € 645,476. Compared with financial year 2023, the result moved from € -177,223 to € -205,565. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 20, 2025.
€ 645,476
▼ 22% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -205,565
▼ 16 % more loss than in 2023
Profit after tax over the fiscal year.
€ 136,276
▼ 74% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -479,376.
People and assets in 2024
2.8
▼ 0.3 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 146,769
▼ 25% vs 2023
€ 52,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,520
▼ 33% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
€ 185,208
€ 59,000 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 12,737
▼ 67% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 23,752
▼ 16% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | - | € 39,696 | € 84,622 | € 74,768 | ▼ 12% |
| Gross margin | € 28,536 | € 85,589 | € 58,991 | € -24,402 | ▼ € 83,393 |
| Profit after taxes | € -39,855 | € -50,512 | € -177,223 | € -205,565 | ▼ € 28,342 |
| Equity | € 248,467 | € 333,944 | € 824,640 | € 645,476 | ▼ 22% |
| Total debts | € 401,884 | € 371,547 | € 406,509 | € 305,203 | ▼ 25% |
| Cash | € 203,450 | € 99,567 | € 521,852 | € 136,276 | ▼ 74% |
| Retained profit | € -46,075 | € -96,587 | € -273,811 | € -479,376 | ▼ € 205,565 |
| Bank debt | € 191,939 | € 234,477 | € 184,897 | € 185,208 | |
| Balance sheet total | € 650,351 | € 705,491 | € 1,231,149 | € 950,679 | ▼ 23% |
| Employees (FTE) | 1 | 1.8 | 3.1 | 2.8 | ▼ 0.3 |
Key figures of THERATOPIX PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to THERATOPIX PHARMA?
What happened at THERATOPIX PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
THERATOPIX PHARMA is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.
- New annual accounts for financial year 2024: loss of € 205,565. Source: NBB ↗
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 39,855 loss in 2021 to € 205,565 loss in 2024.
On average € 19,000 of value added per employee in 2023.
A new publication or filing at THERATOPIX PHARMA? We notify you, reason included.
Follow THERATOPIX PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Establishments
Establishment units
Physical locations of this company
Rue Louvrex 55-57
4000 Liège
Avenue Pré-Aily 10
4031 Liège
Active since 26 November 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →EXIMPA
LM GESTION
€ 305,980 gross margin · 2024
LASERFLASH
€ 1.7 million gross margin · 2023
Agence locale pour l'Emploi de Villers-le-Bouillet
SPARX INDUSTRIES
€ 19.7 million revenue · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0738.446.251
- VAT number
- BE 0738.446.251
- Registered office
- Rue Louvrex 55-57, 4000 Liège
- Names & denominations
- THERATOPIX PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 26 November 2019
- Peppol
- Active · Active since 9 Apr 2026
- Activities · NACE
Vervaardiging van overige farmaceutische producten
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van parfums en toiletartikelen
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige gespecialiseerde wetenschappelijke en technische activiteiten